Drugs / Fibroblast
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03140319 | Dec 2020 → Nov 2021 | skin atrophy | SCARM Institute, Tabriz, Iran | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01115634 | Sep 2008 → Sep 2015 | acne | Royan Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fibroblast | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03140319 ↗ |
| Modality | Cell therapy | “Autologous cultured fibroblast is derived from in vitro expansion of fibroblasts harvested from the patient's normal skin.” NCT01115634 ↗ |
| Route | Other | “received 3 injections of autologous cultured fibroblasts administered at 4-6 week intervals” PMID 31606970 ↗ Sep 2019 |